

# Cross-Sectional Survey of Rheumatologists and Dermatologists to Assess the Effectiveness of the Baricitinib Additional Risk Minimization Measures in Canada

**First published:** 14/01/2025

**Last updated:** 13/02/2025

Study

Planned

## Administrative details

### EU PAS number

EUPAS1000000438

### Study ID

1000000438

### DARWIN EU® study

No

### Study countries

☐ Canada

## Study description

Survey study of HCPs to assess effectiveness of aRMM.

---

## Study status

Planned

## Research institutions and networks

### Institutions

#### YOLARX Consultants

☐ France

**First published:** 30/07/2018

**Last updated:** 06/03/2024

**Institution**

**Non-Pharmaceutical company**

**ENCePP partner**

## Contact details

### Study institution contact

Kristin Meyers meyers\_kristin\_joy@lilly.com

**Study contact**

[meyers\\_kristin\\_joy@lilly.com](mailto:meyers_kristin_joy@lilly.com)

### Primary lead investigator

Philippe Assad

**Primary lead investigator**

## Study timelines

### **Date when funding contract was signed**

Planned: 24/09/2024

Actual: 23/07/2024

---

### **Study start date**

Planned: 03/02/2025

---

### **Date of final study report**

Planned: 01/04/2026

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Eli Lilly and Company

## Study protocol

[LY3009104 B042 NI Canada Protocol Version 1.pdf](#)(754.47 KB)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

Non-EU RMP only

## Other study registration identification numbers and links

## Methodological aspects

### Study type

#### Study type list

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

**Data collection methods:**

Primary data collection

---

### Study drug and medical condition

**Name of medicine**

OLUMIANT

---

**Name of medicine, other**

baricitinib

## Data management

### Use of a Common Data Model (CDM)

**CDM mapping**

No

Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

Data characterisation

**Data characterisation conducted**

No